Compare RS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RS | ROIV |
|---|---|---|
| Founded | 1939 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 23.2B |
| IPO Year | 1996 | 2021 |
| Metric | RS | ROIV |
|---|---|---|
| Price | $403.54 | $33.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $358.00 | $28.94 |
| AVG Volume (30 Days) | 322.2K | ★ 4.4M |
| Earning Date | 04-22-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.10 | N/A |
| Revenue | ★ $14,805,900,000.00 | $8,260,000.00 |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $0.82 | $744.61 |
| P/E Ratio | $81.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $260.31 | $10.90 |
| 52 Week High | $419.83 | $37.00 |
| Indicator | RS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 46.42 |
| Support Level | $379.91 | $26.65 |
| Resistance Level | $419.83 | $37.00 |
| Average True Range (ATR) | 10.99 | 1.10 |
| MACD | 2.75 | -0.34 |
| Stochastic Oscillator | 81.22 | 4.93 |
Reliance Inc operates a network of companies providing diversified metal solutions and is the metals service center company. It distributes a full line of over 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium and other specialty steel products. The company services more than 125,000 customers in a variety of industries, including consumer products, general manufacturing, non-residential construction, transportation, aerospace, energy, electronics and semiconductor fabrication, industrial machinery and heavy industry. It also services the auto industry, through its toll processing operations where it processes customer-owned metal for a fee.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.